Illumina, Inc.
HealthcareNASDAQ:ILMN · NASDAQ Global Select
-$5.02 today
Vol 1.46M · Avg 1.65M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
31.2%
avg 2.5%
ROIC
12.0%
avg 1.2%
ROA
12.8%
avg 2.0%
Analysis
ROE is currently the strongest return metric at 31.2% versus its period average of 2.5%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jacob Thaysen | CEO, Interim Chief Commercial Officer & Director | $2.26M | — | 51 | $109,073.00 | 0.07% |
Ankur Dhingra | Chief Financial Officer | $985,992.00 | — | 50 | $34,264.00 | 0.02% |
Steven Barnard | Chief Technology Officer | $917,976.00 | — | 65 | $41,335.00 | 0.03% |
Kevin Carl Pegels | Chief of Global Operations | $882,992.00 | — | 58 | $29,038.00 | 0.02% |
Mark Field | Chief Information Officer | $693,519.00 | — | 55 | $16,575.00 | 0.01% |
Scott Davies | Chief Legal Officer & Secretary | — | — | 56 | $21,568.00 | 0.01% |
Scott Ericksen | Vice President & Chief Accounting Officer | — | — | 53 | $21,568.00 | 0.01% |
Patricia Leckman | Senior Vice President & Chief People Officer | — | — | 62 | $21,261.00 | 0.01% |
Conor Noel McNamara | Vice President of Investor Relations | — | — | — | — | — |
Stephanie Campos | President | — | — | — | — | — |
Jakob Wedel | Chief Strategy & Corporate Development Officer | — | — | 54 | $15,056.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$84,627.00
Sells
42
$156.28M
Net Sentiment
$156.19M
Net selling
Most Active
Meister Keith A.
26 transactions
1–10 of 44
Analysis
Insiders reported 2 buys worth $84,627.00 and 42 sells worth $156.28M over the last 12 months. That adds up to net selling of $156.19M. Meister Keith A. was the most active insider with 26 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +40.0% | +7.2% (15yr)2 analysts |
| Revenue | N/A | N/A | +24.6% | +6.6% (15yr)10 analysts |
| Net Income | N/A | N/A | +45.0% | +7.6% (15yr)10 analysts |
| EBIT | N/A | N/A | +45.1% | N/A10 analysts |
Analysis
Recent growth has been strongest in EBIT at +45.1% over three years. Forward estimates point to Net Income at +7.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
West Pharmaceutical Services, Inc.
NYSE:WST
$23.28B
Waters Corporation
NYSE:WAT
$23.17B
Quest Diagnostics Incorporated
NYSE:DGX
$22.44B
Labcorp Holdings Inc.
NYSE:LH
$21.65B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.12B
Hologic, Inc.
HOLX
$16.97B
Genmab A/S
NASDAQ:GMAB
$15.37B
Tenet Healthcare Corporation
NYSE:THC
$15.27B
Medpace Holdings, Inc.
NASDAQ:MEDP
$13.42B
ICON Public Limited Company
NASDAQ:ICLR
$11.16B
Who manages ILMN?
Illumina, Inc. (ILMN) lists 11 active executives. The top listed executive is Jacob Thaysen, CEO, Interim Chief Commercial Officer & Director.
Are ILMN insiders buying or selling?
Recent insider activity shows net selling of $202.57M.
Explore More
Continue the stock analysis
Jump to another research area for this company.